Autolus Therapeutics plc
Close on Oct 19, 2026
- Market cap
- $423.19M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | Before market open | $45.69M | $-0.15 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | Before market open | $26.20M | $-0.27 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 27, 2026 | Before market open | $24.29M | $-0.34 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | $21.10M | $-0.30 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | Before market open | $20.90M | $-0.18 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $9.00M | $-0.26 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 20, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | $-0.31 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 17, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 14, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 11, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| AUCATZYL net product revenue | full year 2026 | $140.00M to $150.00M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Autolus Therapeutics filed with the SEC
1 Gross margin percentage represents gross margin (net product revenue less cost of sales) divided by net product revenue
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q2 2026 Financial Results and Business Updates August 11, 2026 Autolus.com For Investor communication only. Not for use in product promotion. Not for further distribution. EX 99-2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Other events · EX-99.3 to Form 8-K
Amanda Cray +1 617-967-0207 [email protected]
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q1 2026 Financial Results and Business Updates May 14, 2026 Autolus.com For Investor communication only. Not for use in product promotion. Not for further distribution. EX-99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
Spotlight on the Acute Lymphoblastic Leukemia (ALL) Business AUTOLUS INVESTOR EVENT April 8, 2026 EX-99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q4 2025 Financial Results and Business Updates March 27, 2026 Autolus.com For Investor communication only. Not for use in product promotion. Not for further distribution. EX-99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Developing Next Generation Programmed T Cell Therapies January 2026 Autolus.com For Investor communication only. Not for use in product promotion. EX-99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Q3 2025 Financial Results and Business Updates November 12, 2025 Autolus.com For Investor communication only. Not for use in product promotion. Not for further distribution. EX-99.2
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q2 2025 Financial Results and Business Updates August 12, 2025 Autolus.com For Investor communication only. Not for use in product promotion. Not for further distribution. EX-99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Other events · EX-99.3 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q1 2025 Financial Results and Business Updates May 8, 2025 Autolus.com For Investor communication only. Not for use in product promotion. Not for further distribution. Ex-99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q4 2024 Financial Results and Business Updates 20 March 2025 Autolus.com For Investor communication only. Not for use in product promotion. Not for further distribution. Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Developing Next Generation Programmed T Cell Therapies January 2025 Autolus.com
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q3 2024 Financial Results and Business Updates 12 November 2024 Autolus.com For Investor communication only. Not for use in product promotion. Not for further distribution. EX-99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Autolus.com FDA Approval Conference Call AUCATZYL® (obecabtagene autoleucel) For Investor communication only. Not for use in product promotion. Not for further distribution. EX-99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Developing Next Generation Programmed T Cell Therapies September 2024 Autolus.com EX-99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q2 2024 Financial Results and Business Updates 8 August 2024 Autolus.com EX-99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Other events · EX-99.3 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
American Society of Clinical Oncology Analyst Call 1 June 2024 Autolus.com
Regulation FD disclosure · EX-99.2 to Form 8-K